HomeCompareKITAF vs MRK

KITAF vs MRK: Dividend Comparison 2026

KITAF yields 2.08% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $10.5K in total portfolio value
10 years
KITAF
KITAF
● Live price
2.08%
Share price
$0.97
Annual div
$0.02
5Y div CAGR
-36.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$2.25
Full KITAF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — KITAF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKITAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KITAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KITAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KITAF
Annual income on $10K today (after 15% tax)
$177.19/yr
After 10yr DRIP, annual income (after tax)
$1.91/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $805.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KITAF + MRK for your $10,000?

KITAF: 50%MRK: 50%
100% MRK50/50100% KITAF
Portfolio after 10yr
$25.5K
Annual income
$476.28/yr
Blended yield
1.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

KITAF
No analyst data
Altman Z
15.8
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KITAF buys
0
MRK buys
0
No recent congressional trades found for KITAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKITAFMRK
Forward yield2.08%3.25%
Annual dividend / share$0.02$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR-36.6%8.2%
Portfolio after 10y$20.3K$30.7K
Annual income after 10y$2.25$950.29
Total dividends collected$362.00$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KITAF vs MRK ($10,000, DRIP)

YearKITAF PortfolioKITAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,832$132.16$11,192$351.54$360.00MRK
2$11,675$84.82$12,524$392.70$849.00MRK
3$12,547$54.17$14,015$438.65$1.5KMRK
4$13,459$34.49$15,682$489.96$2.2KMRK
5$14,424$21.93$17,547$547.23$3.1KMRK
6$15,447$13.92$19,632$611.16$4.2KMRK
7$16,537$8.83$21,963$682.53$5.4KMRK
8$17,700$5.60$24,571$762.18$6.9KMRK
9$18,943$3.55$27,486$851.08$8.5KMRK
10$20,271$2.25$30,745$950.29$10.5KMRK

KITAF vs MRK: Complete Analysis 2026

KITAFStock

Kitanotatsujin Corporation plans, develops, manufactures, and sells health foods, cosmetics, and miscellaneous goods in Japan. It offers health foods and beauty products under the J North Farm brand. The company also sell its products through its e-commerce website. Kitanotatsujin Corporation was founded in 2000 and is headquartered in Sapporo, Japan.

Full KITAF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this KITAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KITAF vs SCHDKITAF vs JEPIKITAF vs OKITAF vs KOKITAF vs MAINKITAF vs JNJKITAF vs ABBVKITAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.